Alnylam Pharmaceuticals
ALNY
#624
Rank
ยฃ25.67 B
Marketcap
ยฃ198.31
Share price
-0.16%
Change (1 day)
54.25%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -ยฃ3.30

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -ยฃ3.25. In 2022 the company made an earnings per share (EPS) of -ยฃ7.35 a decrease over its 2021 EPS that were of -ยฃ5.70.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ3.30-55.07%
2022-ยฃ7.3529.03%
2021-ยฃ5.70-3.36%
2020-ยฃ5.90-8.48%
2019-ยฃ6.447.67%
2018-ยฃ5.9839.74%
2017-ยฃ4.2812.94%
2016-ยฃ3.7938.84%
2015-ยฃ2.73-32.88%
2014-ยฃ4.07259.44%
2013-ยฃ1.13-31.25%
2012-ยฃ1.6552.94%
2011-ยฃ1.0830.77%
2010-ยฃ0.82-8.77%
2009-ยฃ0.9078.13%
2008-ยฃ0.51-70.78%
2007-ยฃ1.7399.09%
2006-ยฃ0.87-43.88%
2005-ยฃ1.55-82.33%
2004-ยฃ8.78-59.23%
2003-ยฃ21.53

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ1.35-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ29.57-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ6.20 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.21-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ1.34-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.96-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ2.52-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-ยฃ1.58-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel